

Allergy (Allergen) Immunotherapy

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

The Plan members who have severe allergies may be eligible for treatment with allergen immunotherapy to alleviate their symptoms. Allergies are often the result of a hypersensitive immune response to specific substances causing an exaggerated reaction. These allergies can develop in response to various antigens including insect bites/stings, seasonal pollen, or certain foods like peanuts. Symptoms include runny nose or congestion, watery or itchy eyes, asthma symptoms, skin rashes or hives, and in severe cases, anaphylaxis. Most allergy cases are successfully treated with over-the-counter medications, although some may require prescriptions in the form of nasal sprays, inhalers, or oral medications to prevent and/or address symptoms. When symptoms are severe or unresponsive to over-the-counter and prescription medication, a specialized type of treatment called allergen immunotherapy may be indicated.

Allergen immunotherapy works by slowly introducing very small amounts of the allergic substance over a prolonged period of time in a controlled environment to train a person's immune system to adapt to the allergic substance. It can be performed with subcutaneous injections (SCIT), sublingual administration (SLIT), or in the case of peanut allergy, oral immunotherapy (OIT) with products like Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp). The administration requirements vary by type:

- SCIT - All doses must be administered in a medically supervised setting equipped to manage adverse reactions.

- SLIT - The first dose must be administered under medical supervision, but subsequent doses can be administered at home, following practice parameters from the American Academy of Allergy, Asthma & Immunology.
- Peanut OIT (Palforzia) - The initial dose escalation and first dose of each dose titration level must be administered in a certified healthcare setting, while subsequent doses are taken daily at home.

NOTE: This policy addresses subcutaneous allergen immunotherapy (SCIT) for certain indications (e.g., respiratory allergies and Hymenoptera [insect] venom allergy). Coverage criteria* for sublingual immunotherapy (SLIT) and food oral immunotherapy (e.g., Palforzia for peanut allergy) are addressed in separate dedicated policies:

- Oscar Clinical Guideline: Allergen Sublingual Immunotherapy (SLIT) (PG093).
- Oscar Clinical Guideline: Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] (PG245)
**Please refer to these policies for specific coverage criteria for SLIT and Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. The Plan reserves the right to modify these policies and/or create additional policies as the evidence and treatment landscape for these modalities evolve. Providers should consult all relevant policies and the member's benefit plan to determine coverage.*

Definitions

“Allergen immunotherapy” is a treatment where very small amounts of an allergic substance are introduced via injection or sublingual administration to a patient with that specific allergy in order to desensitize the immune system.

“Allergy” refers to having both allergen-specific IgE and developing symptoms upon exposure to substances containing that allergen.

“Anaphylaxis” is a severe, systemic immune response (e.g., affecting more than 1 organ system) which may be characterized by flushing, trouble breathing, vomiting/diarrhea, swelling in the mouth/throat, rash, etc. It can be rapidly fatal without immediate treatment.

“Antigen” (or Allergen) refers to an offending substance that causes the allergic reaction through the immune system hypersensitivity. An antigen can be anything from a certain type of pollen to the venom of a bee sting.

“Rapid Desensitization” is an allergen immunotherapy technique where the protocol is performed on a shorter time scale, where standard allergen immunotherapy is performed over longer periods of time (e.g., 3-5 years).

“Sensitization” is when individuals may produce IgE to allergens verified through blood or positive skin tests but do not develop symptoms upon exposure to that substance.

“Subcutaneous” refers to the delivery of medication via injection just under the skin.

“Sublingual” refers to the delivery of medication under a patient’s tongue.

Clinical Indications

Medical Necessity Criteria for Initial Authorization

Subcutaneous immunotherapy (SCIT)

The Plan considers subcutaneous immunotherapy (SCIT) medically necessary for members diagnosed with allergies when ALL the following criteria are met:

1. The member has ONE (1) of the following conditions and meets the condition-specific criteria as below:
 - a. Allergic rhinitis or conjunctivitis, when ALL the following criteria are met:
 - i. The member has experienced ONE (1) or more of the following:
 1. Asthma exacerbation directly linked to allergic rhinitis; *or*
 2. A minimum of 2 consecutive seasons of related allergy symptoms; *or*
 3. Chronic (perennial) allergies; *and*
 - ii. The member has a documented inadequate response after an appropriate trial of ALL of the following, unless specifically contraindicated or poorly tolerated:
 1. Avoidance of environmental or situational antigen exposure; *and*
 2. ONE (1) of the following nasal sprays:
 - a. Nasal antihistamine (e.g., azelastine, olopatadine); *or*
 - b. Nasal cromolyn (sodium cromoglycate); *or*
 - c. Nasal ipratropium; *and*
 3. ONE (1) formulary nasal steroid (e.g., flunisolide, fluticasone, triamcinolone); *and*
 4. ONE (1) of the following oral medication therapies:
 - a. Oral antihistamine (e.g., cetirizine, desloratadine, diphenhydramine); *or*
 - b. Oral antihistamine-decongestant (e.g., cetirizine-pseudoephedrine); *or*
 - c. Oral leukotriene receptor antagonist (e.g., montelukast); *and*
 - iii. There is documented positive skin prick test or serologic IgE test (i.e., in vitro) to the allergen being used for immunotherapy; *and*
 - iv. The condition and allergen are such that there is expected to be a therapeutic benefit to the treatment for that specific allergen; *OR*
 - b. Allergic (extrinsic) asthma, when ALL the following criteria are met:

- i. Forced Expiratory Volume in 1 second (FEV1) is >70% of the predicted age-specific value; *and*
- ii. At least ONE (1) of the following situations is present:
 - 1. Severity of symptoms, when present, prevents normal daily functioning; *or*
 - 2. Symptoms have persisted for 2 or more consecutive seasons or are perennial; *and*
- iii. Documented inadequate response after an appropriate trial of ONE (1) of the following, unless specifically contraindicated or poorly tolerated:
 - 1. Increasing use of short-acting beta2-agonist (e.g., albuterol) or use >2 days/week for symptom relief (not related to incidents of exercise-induced bronchospasm); *or*
 - 2. Diagnosed with persistent asthma needing daily medication within levels Step 2, Step 3, or Step 4 as defined by National Asthma Education and Prevention Program or National Heart, Lung, and Blood Institute (e.g., low-medium dose inhaled corticosteroids, long-acting beta2-agonist, cromolyn, leukotriene receptor antagonist, or theophylline); *and*
- iv. There is documented positive skin prick test or serologic IgE test to the specific allergen being used for immunotherapy; *and*
- v. Avoidance of environmental or situational allergen exposure (e.g, tobacco smoke); *and*
- vi. The condition and allergen are such that there is expected to be a therapeutic benefit to the treatment for that specific allergen; *OR*
- c. Hymenoptera (e.g., bees, ants, hornets, etc.) sting/bite allergy, when ALL the following criteria are met:
 - i. Documented history of anaphylactic or systemic reaction to the suspected offending venom; *and*
 - ii. There is documented serologic or skin allergen-specific IgE test evidence to the venom being used for immunotherapy; *and*
 - iii. Baseline serum tryptase level assessed; *and*
 - iv. The venom immunotherapy (VIT) used is appropriate for the allergen(s) positive on the skin test and is a single preparation (e.g., not mixed); *and*
 - v. The protocol should be as appropriate per manufacturer guidelines (e.g., 1-3 injections per week during the initial treatment phase and then once per 4-12 weeks for maintenance); *and*
 - vi. The total duration of injections should be 3 years, unless member has any of the following circumstances necessitating longer durations:
 - 1. History of severe, life threatening reaction; *or*
 - 2. Honey bee venom allergy; *or*
 - 3. Systemic reactions to VIT; *or*
 - 4. Elevated tryptase from baseline (>11.4 ng/ml); *and*

- vii. The condition and allergen are such that there is expected to be a therapeutic benefit to the treatment for that specific allergen; *AND*
- 2. The member has no contraindications to treatment, including but not limited to any of the following:
 - a. Current pregnancy or breastfeeding (*note; if treatment is started prior to pregnancy or breastfeeding, treatment may be continued in the absence of adverse effects*); *or*
 - b. Concurrent use of beta blockers; *or*
 - c. Moderate to severe asthma or any uncontrolled asthma; *or*
 - d. History of severe reaction to any form of immunotherapy; *or*
 - e. Comorbidities that may reduce ability to survive a severe reaction to the immunotherapy or reduce the effectiveness of epinephrine, including but not limited to:
 - i. Acute or chronic compromised lung function; *or*
 - ii. Significant cardiovascular diseases (e.g., unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension).

Accelerated Schedules for SCIT (Rapid Desensitization, Rush/Cluster Schedules)

The Plan considers SCIT with a rapid desensitization protocol medically necessary when ONE (1) or more of the following situations are present:

- 1. Member meets above general allergen immunotherapy criteria for hymenoptera allergy above *AND* is at a reasonable risk of another bite/sting in the near future; *OR*
- 2. Member has allergic conjunctivitis/rhinitis meeting *ALL* the following criteria:
 - a. The above general allergen immunotherapy criteria are met; *and*
 - b. Symptoms are moderate to severe in intensity; *and*
 - c. Treatment is needed during or immediately before the allergy season; *OR*
- 3. Member is contemplating pregnancy and meets *ALL* of the following criteria:
 - a. The general allergen immunotherapy criteria above are met; *and*
 - b. *ONE* (1) of the following situations is present:
 - i. The current allergy medications would increase risk to the fetus if the member becomes pregnant; *or*
 - ii. Allergen immunotherapy is already being initiated but the member plans to get pregnant within the next 3 years.

Preparation for SCIT

- 1. The preparation of allergen extracts should follow these guidelines:
 - a. Fungal (mold) or cockroach allergen extracts must be prepared and administered individually, not mixed with any other extracts.
 - b. House dust mite, animal dander, and pollen allergens can be mixed together for members sensitized with those specific allergens.
 - c. Venoms should not be mixed, with the exception of the commercially prepared mixed vespid products.

Medical Necessity Criteria for Reauthorization

The initial therapy duration is expected to last at least three years. After three years, therapy may be extended only if there is a documented clinical response meeting ONE (1) of the following criteria:

1. Decreased medication usage; *OR*
2. Improvement in clinical symptoms and sustained benefit from treatment.

Experimental or Investigational / Not Medically Necessary

Allergen immunotherapy for any indication or by any method other than those outlined in this policy or in the Plan's related immunotherapy policies [*Oscar Clinical Guideline: Allergen Sublingual Immunotherapy (SLIT)* (PG093), *Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]* (PG245)] is considered experimental, investigational, or unproven. Non-covered indications and methods include, but are not limited to, the following:

- Home administration of SCIT. According to the Global Initiative for Asthma (GINA) guidelines SCIT should only be prepared and administered by trained healthcare professionals in a healthcare facility which can properly response to a potential severe and/or life-threatening reaction.
- Allergen immunotherapy in the presence of the following contraindications, or any other contraindication listed above:
 - Severe or very labile asthma, as members with unstable asthma are at risk for severe bronchospasm during systemic reactions;
 - Significant cardiovascular disease (e.g., unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension);
 - Pregnancy (see above exception regarding pregnancy medical necessity)
- Allergen immunotherapy for any of the following indications:
 - Bradykinin-induced, idiopathic, or isolated (standalone) angioedema;
 - Atopic dermatitis not related to dust mites;
 - Chronic urticaria;
 - Latex allergy;
 - Medication allergy except as specifically documented above in criteria;
 - Food allergies[†];
 - Intrinsic (non-allergic) asthma;
 - Migraine headaches;
 - Non-allergic vasomotor rhinitis.
- SLIT for any condition other than allergic rhinitis or conjunctivitis (refer to Oscar Clinical Guideline: Allergen Sublingual Immunotherapy (SLIT) (PG093) for SLIT coverage criteria).
- SCIT administered in any other method (i.e., sublingual).
- Venom immunotherapy for severe cutaneous reactions, defined as a generalized rash, swelling, or other skin manifestation of the venom reaction not meeting criteria for anaphylaxis (e.g., no involvement of other organ systems, no swelling of the mouth or throat, etc.).

- Venom immunotherapy for severe local reactions, defined as a reaction localized to the sting/bite site but that does not spread elsewhere in the body and does not meet criteria for anaphylaxis.
 - Repeat skin or serum IgE testing for response to treatment.
- †Oral immunotherapy for food allergies other than FDA-approved products for peanut allergy (refer to Oscar Clinical Guideline: Palforzia [Peanut (*Arachis hypogaea*) Allergen Powder-dnfp] (PG245) for Palforzia coverage criteria).

Applicable Billing Codes (HCPCS/CPT Codes)

<i>Allergen Immunotherapy</i>	
CPT/HCPCS Codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
95115	Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
95117	Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections
95120	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; single injection
95125	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; 2 or more injections
95130	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; single stinging insect venom
95131	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; 2 stinging insect venoms
95132	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; 3 stinging insect venoms
95133	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; 4 stinging insect venoms

95134	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified healthcare professional, including provision of allergenic extract; 5 stinging insect venoms
95144	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials)
95145	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom
95146	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 single stinging insect venoms
95147	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 single stinging insect venoms
95148	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 4 single stinging insect venoms
95149	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 5 single stinging insect venoms
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)
95170	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; whole body extract of biting insect or other arthropod (specify number of doses)
95180	Rapid desensitization procedure, each hour (eg, insulin, penicillin, equine serum) [Rapid/rush/cluster schedules]
ICD-10 codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
H10.10	Acute atopic conjunctivitis, unspecified eye
H10.11	Acute atopic conjunctivitis, right eye
H10.12	Acute atopic conjunctivitis, left eye
H10.13	Acute atopic conjunctivitis, bilateral
H10.44	Vernal conjunctivitis
H10.45	Other chronic allergic conjunctivitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis

J30.5	Allergic rhinitis due to food
J30.8	Other allergic rhinitis
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J45.2	Mild intermittent asthma
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.3	Mild persistent asthma
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.4	Moderate persistent asthma
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.5	Severe persistent asthma
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.9	Other and unspecified asthma
J45.90	Unspecified asthma
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.99	Other asthma
J45.990	Exercise induced bronchospasm
J45.991	Cough variant asthma
J45.998	Other asthma
J67.0	Farmer's lung
J67.1	Bagassosis
J67.2	Bird fancier's lung
J67.3	Suberosis

J67.4	Maltworker's lung
J67.5	Mushroom-worker's lung
J67.6	Maple-bark-stripper's lung
J67.7	Air conditioner and humidifier lung
J67.8	Hypersensitivity pneumonitis due to other organic dusts
J67.9	Hypersensitivity pneumonitis due to unspecified organic dust
J82.83	Eosinophilic asthma
T63.42	Toxic effect of venom of ants
T63.421	Toxic effect of venom of ants, accidental (unintentional)
T63.421A	Toxic effect of venom of ants, accidental (unintentional), initial encounter
T63.421D	Toxic effect of venom of ants, accidental (unintentional), subsequent encounter
T63.421S	Toxic effect of venom of ants, accidental (unintentional), sequela
T63.422	Toxic effect of venom of ants, intentional self-harm
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter
T63.422D	Toxic effect of venom of ants, intentional self-harm, subsequent encounter
T63.422S	Toxic effect of venom of ants, intentional self-harm, sequela
T63.423	Toxic effect of venom of ants, assault
T63.423A	Toxic effect of venom of ants, assault, initial encounter
T63.423D	Toxic effect of venom of ants, assault, subsequent encounter
T63.423S	Toxic effect of venom of ants, assault, sequela
T63.424	Toxic effect of venom of ants, undetermined
T63.424A	Toxic effect of venom of ants, undetermined, initial encounter
T63.424D	Toxic effect of venom of ants, undetermined, subsequent encounter
T63.424S	Toxic effect of venom of ants, undetermined, sequela
T63.44	Toxic effect of venom of bees
T63.441	Toxic effect of venom of bees, accidental (unintentional)
T63.441A	Toxic effect of venom of bees, accidental (unintentional), initial encounter
T63.441D	Toxic effect of venom of bees, accidental (unintentional), subsequent encounter
T63.441S	Toxic effect of venom of bees, accidental (unintentional), sequela
T63.442	Toxic effect of venom of bees, intentional self-harm
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter
T63.442D	Toxic effect of venom of bees, intentional self-harm, subsequent encounter
T63.442S	Toxic effect of venom of bees, intentional self-harm, sequela
T63.443	Toxic effect of venom of bees, assault

T63.443A	Toxic effect of venom of bees, assault, initial encounter
T63.443D	Toxic effect of venom of bees, assault, subsequent encounter
T63.443S	Toxic effect of venom of bees, assault, sequela
T63.444	Toxic effect of venom of bees, undetermined
T63.444A	Toxic effect of venom of bees, undetermined, initial encounter
T63.444D	Toxic effect of venom of bees, undetermined, subsequent encounter
T63.444S	Toxic effect of venom of bees, undetermined, sequela
T63.45	Toxic effect of venom of hornets
T63.451	Toxic effect of venom of hornets, accidental (unintentional)
T63.451A	Toxic effect of venom of hornets, accidental (unintentional), initial encounter
T63.451D	Toxic effect of venom of hornets, accidental (unintentional), subsequent encounter
T63.451S	Toxic effect of venom of hornets, accidental (unintentional), sequela
T63.452	Toxic effect of venom of hornets, intentional self-harm
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter
T63.452D	Toxic effect of venom of hornets, intentional self-harm, subsequent encounter
T63.452S	Toxic effect of venom of hornets, intentional self-harm, sequela
T63.453	Toxic effect of venom of hornets, assault
T63.453A	Toxic effect of venom of hornets, assault, initial encounter
T63.453D	Toxic effect of venom of hornets, assault, subsequent encounter
T63.453S	Toxic effect of venom of hornets, assault, sequela
T63.454	Toxic effect of venom of hornets, undetermined
T63.454A	Toxic effect of venom of hornets, undetermined, initial encounter
T63.454D	Toxic effect of venom of hornets, undetermined, subsequent encounter
T63.454S	Toxic effect of venom of hornets, undetermined, sequela
T63.46	Toxic effect of venom of wasps
T63.461	Toxic effect of venom of wasps, accidental (unintentional)
T63.461A	Toxic effect of venom of wasps, accidental (unintentional), initial encounter
T63.461D	Toxic effect of venom of wasps, accidental (unintentional), subsequent encounter
T63.461S	Toxic effect of venom of wasps, accidental (unintentional), sequela
T63.462	Toxic effect of venom of wasps, intentional self-harm
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter
T63.462D	Toxic effect of venom of wasps, intentional self-harm, subsequent encounter
T63.462S	Toxic effect of venom of wasps, intentional self-harm, sequela

T63.463	Toxic effect of venom of wasps, assault
T63.463A	Toxic effect of venom of wasps, assault, initial encounter
T63.463D	Toxic effect of venom of wasps, assault, subsequent encounter
T63.463S	Toxic effect of venom of wasps, assault, sequela
T63.464	Toxic effect of venom of wasps, undetermined
T63.464A	Toxic effect of venom of wasps, undetermined, initial encounter
T63.464D	Toxic effect of venom of wasps, undetermined, subsequent encounter
T63.464S	Toxic effect of venom of wasps, undetermined, sequela
Z91.03	Insect allergy status
Z91.030	Bee allergy status
Z91.038	Other insect allergy status

References

1. 2024 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WM_S.pdf. Accessed 5 September 2025.
2. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD001186. doi: 10.1002/14651858.CD001186.pub2.
3. Akdis M. Allergen immunotherapy for allergic disease: Therapeutic mechanisms. UpToDate. UpToDate.com. Waltham, MA. Last updated Sept 2018.
4. American Academy of Allergy Asthma and Immunology. The current state of oral immunotherapy (OIT) for the treatment of food allergy. Available at: <https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/the-current-state-of-oral-immunotherapy>.
5. Bousquet et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019 Nov; 74(11):2087-2102
6. Bousquet J, Calvayrac P, Guérin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 1985 Nov;76(5):734-44. doi: 10.1016/0091-6749(85)90680-3.
7. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol. 1988 Dec;82(6):971-7. doi: 10.1016/0091-6749(88)90133-9.
8. Bozek A, Pyrkosz. Immunotherapy of mold allergy: A review. Hum Vaccin Immunother. 2017; 13(10): 2397–2401. doi: 10.1080/21645515.2017.1314404
9. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. The Journal of Allergy and Clinical Immunology. 2013;131(5):1288-1296. doi: <https://doi.org/10.1016/j.jaci.2013.01.049>
10. Calabria CW, Stolfi A, Tankersley MS. The REPEAT study: recognizing and evaluating periodic local reactions in allergen immunotherapy and associated systemic reactions. Ann Allergy Asthma Immunol 2011; 106:49.
11. Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy

- strategies in polysensitized patients: Looking at the published evidence. *J Allergy Clin Immunol*. 2012;129 (4): 929-934
12. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. *J Allergy Clin Immunol*. 2010 Mar;125(3):569-74, 574.e1-574.e7. doi: 10.1016/j.jaci.2009.10.060. Epub 2010 Feb 7.
 13. Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., ... & Wallace, D. (2011). Allergen immunotherapy: a practice parameter third update. *Journal of Allergy and Clinical Immunology*, 127(1), S1-S55. doi:10.1016/j.jaci.2010.09.034
 14. CMS. Medicare Claims Processing Manual Chapter 12 - Physicians/Nonphysician Practitioners. cms.gov. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c12.pdf> Revised Nov 2019. Accessed May 2020.
 15. Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2014; 133:751.
 16. Creticos PS. Subcutaneous immunotherapy for allergic disease: Indications and efficacy. UpToDate. UpToDate.com. Waltham, MA. Last updated Aug 2019.
 17. Creticos PS. Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. UpToDate. UpToDate.com. Waltham, MA. Last updated May 2019.
 18. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. *N Engl J Med*. 1996 Feb 22;334(8):501-6. doi: 10.1056/NEJM199602223340804.
 19. deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. UpToDate. UpToDate.com. Waltham, MA. Last updated April 2020.
 20. Dunlop JH. Oral immunotherapy for treatment of peanut allergy. *J Investig Med*. 2020 Aug;68(6):1152-1155. doi: 10.1136/jim-2020-001422. Epub 2020 Jul 14. PMID: 32665367.
 21. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. *JACI*. 2020;146(4):721-767.
 22. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. *Ann Allergy Asthma Immunol*. 2017; 119:489.
 23. Du Toit G, Brown KR, Vereda A, Irani AM, Tilles S, Ratnayake A, Jones SM, Vickery BP. Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age. *NEJM Evid*. 2023 Nov;2(11):EVIDoa2300145. doi: 10.1056/EVIDoa2300145. Epub 2023 Oct 23. PMID: 38320526.
 24. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPCC); Cloutier MM, Baptist AP, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol*. 2020 Dec;146(6):1217-1270. doi: 10.1016/j.jaci.2020.10.003. Erratum in: *J Allergy Clin Immunol*. 2021 Apr;147(4):1528-1530. doi: 10.1016/j.jaci.2021.02.010.
 25. Fajt ML, Rosenberg SL, Yecies E, et al. A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol. *Allergy Asthma Proc* 2017; 38:309.
 26. Golden DBK. Insect allergy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1005.
 27. Golden, D.B. Demain, J. Freeman, T., et al. (2017). Stinging insect hypersensitivity: A practice parameter update 2016. *Ann Allergy Asthma Immunol*, 118(1), 28. Doi: 10.1016/j.anai.2016.10.031
 28. Golden DBK, Wang J, Wasserman S, et al. Anaphylaxis: A 2023 practice parameter update. *Ann Allergy Asthma Immunol*. 2024 Feb;132(2):124-176. Doi: 10.1016/j.anai.2023.09.015. Epub 2023 Dec 18.
 29. GRASTEK® (Timothy Grass Pollen Allergen Extract) [package insert]. Hørsholm, Denmark: ALK-Abelló A/S; 2014. Revised December 2019. <https://www.fda.gov/media/88510/download>

30. Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. *Ann Allergy Asthma Immunol.* 2017;118(3):276-282.e2.
31. Grier TJ, Hall DM, Duncan EA, et al. Mixing compatibilities of *Aspergillus* and American cockroach allergens with other high-protease fungal and insect extracts. *Ann Allergy Asthma Immunol.* 2015 Mar;114(3):233-9. doi: 10.1016/j.anai.2014.11.021
32. Grier TJ, LeFevre DM, Duncan EA, et al. Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. *Ann Allergy Asthma Immunol.* 2007;99(2):151. doi: 10.1016/S1081-1206(10)60639-4
33. Hayes, Inc. Hayes Health Technology Assessment. *Oral Immunotherapy with Palforzia (peanut allergen powder-dnfp) for the Management of Peanut Allergy.* Lansdale, PA: Hayes, Inc.; April 30, 2020.
34. Jakob T, Rafei-Shamsabadi D, Spillner E, et al. Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics. *Allergo J Int.* 2017;26(3): 93-105. doi: 10.1007/s40629-017-0014-2
35. Jiang, Z., Xiao, H., Zhang, H., Liu, S., & Meng, J. (2019). Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma: A systematic review and meta-analysis. *American Journal of Otolaryngology*, 40(6), 102269.
36. Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. *J Allergy Clin Immunol.* 2015;136(3):556-68.
37. Korošec P, Jakob T, Harb H, et al. Worldwide perspectives on venom allergy. *World Allergy Organ J.* 2019 Oct 24;12(10):100067. doi: 10.1016/j.waojou.2019.100067.
38. Lin SY, Ereksom N, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: Comparative Effectiveness Review No. 111. AHRQ; Agency for Healthcare Research and Quality, Rockville, MD 2013.
39. Mustillo, P., Martin B.L., Oppenheimer J., and Nelson M.R. (2019). Allergen Immunotherapy Extract Preparation Instructional Guide. <https://college.acaai.org/sites/default/files/acaai-mixinginstructionguide.pdf>
40. National Asthma Education and Prevention Program (NAEPP) Coordinating Committee (CC) and National Heart, Lung, and Blood Institute of National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma (EPR-3) Asthma Care Quick Reference: Diagnosing and Managing Asthma. https://www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf Updated September 2012. Accessed April 2020.
41. Nelson HS. Subcutaneous injection immunotherapy for optimal effectiveness. *Immunol Allergy Clin North Am.* 2011;31(2):211-26. doi: 10.1016/j.iac.2011.02.010.
42. Nelson, H. S. (2020). 2020 Updated Asthma Guidelines: Allergen immunotherapy. *Journal of Allergy and Clinical Immunology*, 146(6), 1286-1287
43. Nelson H. SCIT: Standard schedules, administration techniques, adverse reactions, and monitoring. UpToDate.com. Waltham, MA. Last updated Oct 2018.
44. Nelson H. SCIT: Preparation of allergen extracts for therapeutic use. UpToDate. <https://www.uptodate.com/contents/scit-preparation-of-allergen-extracts-for-therapeutic-use#H24981603> Last updated Aug 2019. Accessed May 2020.
45. Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. *Cochrane Database Syst Rev* 2015; :CD011293.
46. ODACTRA™ House Dust Mite (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract [package insert]. Hørsholm, Denmark: ALK-Abelló A/S; published 2018. Revised August 2019. <https://www.fda.gov/media/103380/download>
47. ORALAIR® 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) [package insert]. Antony, France: Stallergenes SAS; published 2014. Revised November 2018. <https://www.fda.gov/media/87935/download>
48. Palforzia (peanut [*Arachis hypogaea*] allergen powder) [prescribing information]. Bridgewater, NJ: Aimmune Therapeutics Inc; July 2024.

49. PALISADE Group of Clinical Investigators; Vickery et al. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med*. 2018 Nov 22;379(21):1991-2001. doi: 10.1056/NEJMoa1812856. Epub 2018 Nov 18. PMID: 30449234.
50. Patrawala M, Shih J, Lee G, Vickery B. Peanut Oral Immunotherapy: a Current Perspective. *Curr Allergy Asthma Rep*. 2020 Apr 20;20(5):14. doi: 10.1007/s11882-020-00908-6. PMID: 32314071; PMCID: PMC7223701.
51. Pepper et al. Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. *J Allergy Clin Immunol*. 2020 Aug;146(2):244-249. doi: 10.1016/j.jaci.2020.05.027. Epub 2020 Jun 4. PMID: 32505612.
52. Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. *European Journal of Allergy and Clinical Immunology*. 2015; 70(8): 897-909. doi: <https://doi.org/10.1111/all.12638>
53. RAGWITEK® (Short Ragweed Pollen Allergen Extract) [package insert]. Wiltshir, UK: Catalent Pharma Solutions Limited; published 2014. Revised April 2017. <https://www.fda.gov/media/88712/download>
54. Real-world experience of pediatric patients treated with peanut (*Arachis hypogaea*) allergen powder-dnfp. Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latremouille-Viau D, Bungay R, Chen K, McCann W - *Ann Allergy Asthma Immunol* - January 1, 2023; 130 (5); 649-656.e4
55. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. *Clin Ther*. 2000 Mar;22(3):342-50. doi: 10.1016/S0149-2918(00)80038-7.
56. Sampson et al. Food allergy: a practice parameter update-2014. *J Allergy Clin Immunol*. 2014 Nov;134(5):1016-25.e43. doi: 10.1016/j.jaci.2014.05.013. Epub 2014 Aug 28. PMID: 25174862.
57. Serota M. Subcutaneous aeroallergen immunotherapy: Accelerated schedules (cluster and rush). UpToDate. UpToDate.com. Waltham, MA. Last updated Apr 2020.
58. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. *Otolaryngol Head Neck Surg* 2015; 152:S1.
59. Shaker M, Greenhawt M. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis. *JAMA Netw Open*. 2019 May 3;2(5):e193242. doi: 10.1001/jamanetworkopen.2019.3242. PMID: 31050778; PMCID: PMC6503512.
60. Sturm, G.J, Varga, E.M., Roberts, G., et al. (2018, April). EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. *Allergy*, 73 (4), 744-764. Doi: <https://doi.org/10.1111/all.13262>
61. Tabar AI, Echechipía S, García BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with *Dermatophagoides pteronyssinus*. *J Allergy Clin Immunol* 2005; 116:109.
62. The Joint Task Force on Practice Parameters of Allergy, Asthma & Immunology. Allergen immunotherapy: A practice parameter third update. *The Journal of Allergy and Clinical Immunology*. 2011;127(1). doi:10.1016/j.jaci.2010.09.034 <https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Allergen-immunotherapy-Jan-2011.pdf>
63. The Joint Task Force on Practice Parameters of Allergy, Asthma & Immunology. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. *Ann Allergy Asthma Immunol*. 2017;118 ():276-282. doi:<https://doi.org/10.1016/j.anai.2016.12.009> <https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Sublingual-Immunotherapy-2017.pdf>
64. Togias et al. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. *J Allergy Clin Immunol*. 2017 Jan;139(1):29-44. doi: 10.1016/j.jaci.2016.10.010. PMID: 28065278; PMCID: PMC5226648.

65. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. *J Allergy Clin Immunol*. 2001 Jan;107(1):87-93. doi: 10.1067/mai.2001.112027.
66. Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters. *Ann Intern Med* 2017; 167:876.
67. Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. *J Allergy Clin Immunol* 2012; 130:886.
68. Wenzel, S. (March 2021). *Treatment of severe asthma in adolescents and adults*. UpToDate.com. https://www.uptodate.com/contents/treatment-of-severe-asthma-in-adolescents-and-adults?search=eosinophilic%20asthma&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
69. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. *Int Forum Allergy Rhinol*. 2023 Apr;13(4):293-859. doi: 10.1002/alr.23090. Epub 2023 Mar 6.
70. Wood et al. Omalizumab for the Treatment of Multiple Food Allergies. *N Engl J Med*. 2024 Mar 7;390(10):889-899. doi: 10.1056/NEJMoa2312382. Epub 2024 Feb 25. PMID: 38407394; PMCID: PMC11193494.
71. Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. *Clin Transl Allergy* 2014; 4:7.
72. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, et al. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. *J Allergy Clin Immunol*. 2023 Jan;151(1):147-158. doi: 10.1016/j.jaci.2022.09.020. Epub 2022 Sep 30.
73. Zuraw, B. (2021). An overview of angioedema: Clinical features, diagnosis, and management. UpToDate.com. Waltham, MA. Last updated May 27, 2021.

Clinical Guideline Revision / History Information

Original Date: 7/21/2020

Reviewed/Revised: 06/24/2021, 12/01/2021, 06/23/2022, 06/29/2023, 09/18/2024, 11/01/2025